DOI: https://doi.org/10.36347/sjmcr.2025.v13i11.037

Pages: 2820-2824

Autologous platelet-rich plasma (PRP) has emerged as a promising regenerative therapy for refractory corneal ulcers. This prospective, non-randomized interventional study evaluated 21 corneal ulcers in 16 patients unresponsive to at least 15 days of conventional therapy, including vitamin A ointment, preservative-free lubricants, and occlusive patching. Patients received topical autologous PRP (1 drop, four times daily) in combination with supportive therapy. Clinical outcomes assessed included ulcer dimensions, visual acuity, and ocular symptom improvement. Median treatment duration was 21 days (range 15–60). Complete re-epithelialization was achieved in 71.4% of ulcers, with mean ulcer height and width decreasing by 86.2% and 83.0%, respectively (p < 0.01). Visual acuity improved by three lines in 31.25% and by two lines in 25% of patients. Significant reductions were observed in pain (p < 0.05), redness (p < 0.01), visual impairment (p < 0.01), and photophobia (p = 0.01). One patient developed corneal neovascularization. These results demonstrate that autologous PRP is a safe and effective therapy for promoting corneal healing, reducing ulcer size, and improving visual function and ocular comfort in refractory cases. Further standardization of PRP preparation and dosing protocols is warranted to optimize clinical outcomes and facilitate broader adoption in ophthalmic practice.